Calcium channel blockers (versus unexposed)

Neonatal medical care

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S13969
R54758		 Parazzini - Nifedipine, 1998 Admission to neonatal care unit for intensive care 2nd and/or 3rd trimester randomized controlled trial unexposed, sick Adjustment: Randomisation Indications Antihypertensive: All hypertensions, any indications or not specified 1.80 [0.70;4.60] 12/123   7/126 19 123
ref
S13986
R54918		 Wide-Swensson - Isradipine, 1995 Neonatal ward 3rd trimester randomized controlled trial unexposed, sick Adjustment: Randomisation Indications Antihypertensive: All hypertensions, any indications or not specified 1.06 [0.41;2.73] C 12/46   11/44 23 46
ref
Total 2 studies 1.38 [0.71;2.70] 42 169
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Parazzini - Nifedipine, 1998Parazzini - Nifedipine, 1998 1.80[0.70; 4.60]1912350%ROB confusion: lowROB selection: unclearROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: moderate Wide-Swensson - Isradipine, 1995Wide-Swensson - Isradipine, 1995 1.06[0.41; 2.73]234650%ROB confusion: lowROB selection: lowROB classification: moderateROB missing: lowROB mesure: lowROB reporting: moderate Total (2 studies) I2 = 0% 1.38[0.71; 2.70]421690.55.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0 case control studiescase control studies 0 RCTRCT 1.38[0.71; 2.70]421690%NAParazzini - Nifedipine, 1998 Wide-Swensson - Isradipine, 1995 2 Type of controls unexposed, sickunexposed, sick 1.38[0.71; 2.70]421690%NAParazzini - Nifedipine, 1998 Wide-Swensson - Isradipine, 1995 2 Tags Adjustment   - Randomisation  - Randomisation 1.38[0.71; 2.70]421690%NAParazzini - Nifedipine, 1998 Wide-Swensson - Isradipine, 1995 2 Indications Antihypertensive   - All hypertensions, any indications ...  - All hypertensions, any indications or not specified 1.38[0.71; 2.70]421690%NAParazzini - Nifedipine, 1998 Wide-Swensson - Isradipine, 1995 2 All studiesAll studies 1.38[0.71; 2.70]421690%NAParazzini - Nifedipine, 1998 Wide-Swensson - Isradipine, 1995 20.55.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed, sick controlsunexposed, sick controls 1.38[0.71; 2.70]421690%NAParazzini - Nifedipine, 1998 Wide-Swensson - Isradipine, 1995 20.510.01.0

Umbrella review (other published meta-analyses)

Published MATE95% CIn exposedkI2Control groupExposition period AbalosAbalos 1.18[0.87; 1.62]14%-unexposed, sickduring pregnancy (anytime or not specified)studies2 Bone - GESTATIONAL HYPERTENSIONBone - GESTATIONAL HYPERTENSION 1.21[0.66; 2.27]27%-unexposed, sickduring pregnancy (anytime or not specified)studies-9 Bone - GESTATIONAL HYPERTENSIONBone - GESTATIONAL HYPERTENSION 1.19[0.43; 3.52]37%-exposed to other treatment, sickduring pregnancy (anytime or not specified)studies-9 Firoz (Nifedipine)Firoz (Nifedipine) 1.00[0.18; 5.51]NA-exposed to other treatment, sickduring pregnancy (anytime or not specified)studies1 George - NifedipineGeorge - Nifedipine 0.98[0.65; 1.47]38%-exposed to other treatment, sickduring pregnancy (anytime or not specified)studies11 George - NifedipineGeorge - Nifedipine 0.98[0.67; 1.43]0%-exposed to other treatment, sickduring pregnancy (anytime or not specified)studies7 Liu - NifedipineLiu - Nifedipine 1.24[0.57; 2.67]NA-exposed to other treatment, sickduring pregnancy (anytime or not specified)studies-9 Shekhar (Intravenous labetalol) - GESTATIONAL ...Shekhar (Intravenous labetalol) - GESTATIONAL HYPERTENSION (DUPLICATE) 1.30[0.88; 1.96]NA-exposed to other treatment, sickduring pregnancy (anytime or not specified)studies5 Shekhar (Intravenous labetalol) - GESTATIONAL ...Shekhar (Intravenous labetalol) - GESTATIONAL HYPERTENSION 1.30[0.88; 1.96]NA-exposed to other treatment, sickduring pregnancy (anytime or not specified)studies5 Shi (Nifedipine) - GESTATIONAL HYPERTENSIONShi (Nifedipine) - GESTATIONAL HYPERTENSION 1.01[0.63; 1.62]0%-exposed to other treatment, sickduring pregnancy (anytime or not specified)studies3 metaPregmetaPreg 1.38[0.71; 2.70]0%169--Parazzini - Nifedipine, 1998 Wide-Swensson - Isradipine, 1995 20.510.01.0